Marsi Bionics

Marsi Bionics operates at the intersection of medical devices, rehabilitation and robotics, focusing on wearable systems intended for clinical rehabilitation and mobility assistance. Its stated product range spans a robotic knee orthosis and pediatric walking exoskeletons, with the company describing its ARES modular technology as supporting configurations from single-joint active orthoses to full trunk, hip, knee, ankle and foot systems. That combination of modularity and products aimed at both pediatric and broader rehabilitation needs distinguishes its stated offering from a company focused on only one device type. The portfolio names Atlas 2030, Explorer MB and Mak, alongside a therapy and research center. The company’s reported categories—Health Care, Rehabilitation, Manufacturing and Robotics—provide a clearer view of its competitive context than the limited peer information does. Six recorded funding events through 2023, including grants, seed financing, crowdfunding and a later venture round, indicate a financing history spanning both public-support and private-capital mechanisms. This profile supports a differentiated product focus, but not a claim of category leadership or commercial scale.

Founded in 2013, Marsi Bionics has followed a long product-development and financing trajectory in a technically demanding medical-device niche. Its first recorded financing was a $158,543 pre-seed round on Nov 30, 2015, followed by a $321,268 seed round in 2016 and a $2,012,418 grant in 2018. A $624,708 seed round in 2019 and $1,152,110 in equity crowdfunding in 2021 preceded the largest recorded financing: a $4,912,396 venture round on Jun 30, 2023. Across six rounds, total funding is $9,181,443. Product milestones include the MAK active knee orthosis, described as CE-marked in April 2020, and the ATLAS pediatric exoskeleton, described as CE-marked in the first half of 2021. The current listed portfolio also includes Explorer MB and the Marsi Care Therapy and Research Center. These developments suggest progression from early engineering and clinical-device development toward a broader product set and user-facing therapy offering.